CPIX RSI Chart
Last 7 days
-1.9%
Last 30 days
-3.8%
Last 90 days
-28.1%
Trailing 12 Months
-14.2%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 38.8M | 0 | 0 | 0 |
2023 | 40.1M | 40.7M | 39.3M | 39.6M |
2022 | 36.6M | 37.9M | 41.2M | 42.0M |
2021 | 39.6M | 39.1M | 37.9M | 36.0M |
2020 | 34.0M | 34.2M | 36.5M | 37.4M |
2019 | 32.2M | 34.5M | 35.6M | 34.4M |
2018 | 37.4M | 35.8M | 30.5M | 29.3M |
2017 | 34.9M | 36.2M | 38.6M | 41.2M |
2016 | 32.6M | 31.1M | 32.0M | 33.0M |
2015 | 37.5M | 36.7M | 34.8M | 33.5M |
2014 | 29.9M | 32.5M | 35.7M | 36.9M |
2013 | 48.9M | 43.6M | 37.6M | 32.0M |
2012 | 50.7M | 48.7M | 48.2M | 48.9M |
2011 | 46.4M | 50.1M | 50.9M | 51.1M |
2010 | 0 | 44.3M | 45.1M | 45.9M |
2009 | 0 | 0 | 0 | 43.5M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 25, 2024 | galante joseph c | acquired | 1,710 | 1.71 | 1,000 | - |
Mar 25, 2024 | young caroline | acquired | 1,710 | 1.71 | 1,000 | - |
Mar 25, 2024 | krogulski kenneth | acquired | 8,550 | 1.71 | 5,000 | - |
Mar 25, 2024 | jones james | acquired | 1,710 | 1.71 | 1,000 | - |
Mar 25, 2024 | brown martin s jr | acquired | 1,710 | 1.71 | 1,000 | - |
Mar 23, 2024 | herman james l | sold (taxes) | -2,146 | 1.81 | -1,186 | vp and chief compliance office |
Mar 23, 2024 | kazimi a j | sold (taxes) | -46,535 | 1.81 | -25,710 | chairman and ceo |
Mar 23, 2024 | bitterman chris t. | sold (taxes) | -1,073 | 1.81 | -593 | vice pres sales & marketing |
Mar 23, 2024 | hamm john m. | sold (taxes) | -805 | 1.81 | -445 | vp chief financial officer |
Mar 23, 2024 | anthony todd m. | sold (taxes) | -1,476 | 1.81 | -816 | vice pres organizational dev |
Which funds bought or sold CPIX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | STATE STREET CORP | reduced | -15.31 | -12,619 | 56,616 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | added | 2.46 | -66.00 | 6,085 | -% |
May 15, 2024 | Royal Bank of Canada | reduced | -65.94 | - | - | -% |
May 15, 2024 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | unchanged | - | -17,200 | 481,580 | 0.01% |
May 15, 2024 | TWO SIGMA INVESTMENTS, LP | reduced | -1.82 | -4,698 | 54,482 | -% |
May 15, 2024 | TWO SIGMA ADVISERS, LP | reduced | -1.71 | -3,286 | 38,640 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 2.11 | -430 | 9,655 | -% |
May 15, 2024 | Cresset Asset Management, LLC | unchanged | - | -1,343 | 20,202 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | sold off | -100 | -9.00 | - | -% |
May 15, 2024 | MORGAN STANLEY | unchanged | - | -1,260 | 18,940 | -% |
Unveiling Cumberland Pharmaceuticals Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Cumberland Pharmaceuticals Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 372.2B | 85.6B | 9.67 | 4.35 | ||||
MRK | 332.3B | 61.4B | 144.1 | 5.41 | ||||
AMGN | 167.7B | 29.5B | 44.55 | 5.68 | ||||
PFE | 162.3B | 57.8B | 129.52 | 2.81 | ||||
GILD | 84.4B | 27.4B | 174.21 | 3.07 | ||||
TEVA | 18.4B | 16.0B | -37.29 | 1.15 | ||||
MID-CAP | ||||||||
ALKS | 4.1B | 1.7B | 9.41 | 2.37 | ||||
PRGO | 4.1B | 4.6B | -528.11 | 0.89 | ||||
BHC | 2.5B | 9.0B | -5.45 | 0.28 | ||||
AMPH | 2.1B | 676.2M | 13.75 | 3.14 | ||||
SMALL-CAP | ||||||||
TLRY | 1.5B | 743.2M | -4.35 | 2.06 | ||||
TXMD | 25.8M | 1.3M | -3.49 | 19.84 | ||||
ACRX | 18.4M | 89.6M | -1.29 | 0.19 | ||||
AGRX | 2.5M | 21.5M | -0.32 | 0.12 | ||||
ACOR | 633.5K | 115.7M | 0 | 0.01 |
Cumberland Pharmaceuticals Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -9.1% | 8,497,701 | 9,353,066 | 10,085,926 | 10,888,877 | 9,224,638 | 9,123,680 | 11,413,072 | 10,299,152 | 11,175,045 | 8,319,861 | 8,072,540 | 9,055,483 | 10,537,159 | 10,261,534 | 9,250,689 | 9,598,177 | 8,330,734 | 9,305,553 | 6,935,439 | 9,417,443 | 8,729,860 |
Costs and Expenses | -33.3% | 10,366,951 | 15,532,305 | 11,952,529 | 10,866,018 | 10,756,316 | 11,401,484 | 11,701,660 | 12,145,690 | 12,467,044 | 12,673,857 | 9,635,935 | 10,491,212 | 10,861,459 | 12,007,480 | 10,459,375 | 11,179,139 | 10,176,735 | 12,699,943 | 10,131,875 | 10,790,867 | 10,053,792 |
S&GA Expenses | -12.7% | 4,154,588 | 4,759,230 | 4,743,142 | 4,672,075 | 4,277,318 | 3,379,434 | 4,110,397 | 4,556,685 | 4,614,429 | 3,305,979 | 3,800,288 | 4,121,817 | 3,787,340 | 3,604,541 | 3,587,842 | 3,865,406 | 3,707,676 | 4,045,962 | 3,812,467 | 3,982,379 | 3,436,932 |
R&D Expenses | -8.4% | 1,158,253 | 1,264,753 | 1,924,768 | 1,145,038 | 1,499,670 | 1,405,841 | 1,714,254 | 1,823,693 | 1,745,136 | 1,612,827 | 1,453,873 | 1,360,398 | 1,257,367 | 1,399,433 | 1,230,335 | 1,421,502 | 1,722,555 | 2,079,782 | 1,672,843 | 1,716,169 | 1,399,687 |
EBITDA Margin | -337.3% | -0.08 | -0.02 | 0.06 | 0.08 | 0.04 | 0.01 | -0.03 | -0.08 | -0.04 | -0.02 | 0.05 | 0.06 | - | - | - | - | - | - | - | - | - |
Interest Expenses | -33.7% | 118,526 | 178,792 | 110,081 | 192,635 | 186,353 | 179,456 | 149,340 | 137,624 | 119,575 | 27,734 | 20,021 | 25,859 | 24,417 | 35,897 | 75,210 | 119,455 | 33,065 | 29,198 | 64,877 | 91,200 | 60,911 |
Income Taxes | -54.2% | 11,442 | 24,956 | 6,938 | 6,937 | 6,938 | 48,150 | 6,900 | 6,900 | 6,900 | 12,516 | 7,458 | 7,459 | 7,458 | 10,479 | 3,728 | 7,455 | 34,240 | -6,812 | 4,462 | 4,462 | -81,428 |
Earnings Before Taxes | 69.9% | -1,891,030 | -6,277,031 | -1,056,281 | 869,091 | 179,224 | -2,411,564 | -416,326 | -1,357,766 | -1,395,533 | -4,375,060 | -1,576,022 | 732,143 | -343,291 | -1,777,051 | -1,271,892 | -1,671,756 | -1,849,178 | -3,376,139 | -3,311,824 | -1,334,059 | -1,268,982 |
EBT Margin | -35.4% | -0.22 | -0.16 | -0.06 | -0.04 | -0.10 | -0.13 | -0.18 | -0.23 | -0.18 | -0.15 | -0.08 | -0.07 | - | - | - | - | - | - | - | - | - |
Net Income | 69.1% | -1,946,263 | -6,294,406 | -1,049,298 | 872,200 | 192,184 | -2,440,729 | -408,639 | -1,335,620 | -1,385,253 | -3,847,697 | -1,055,278 | 1,228,560 | 166,828 | -883,776 | -481,737 | -918,275 | -1,055,620 | -960,706 | -1,953,668 | -549,507 | -73,878 |
Net Income Margin | -36.6% | -0.22 | -0.16 | -0.06 | -0.04 | -0.10 | -0.13 | -0.17 | -0.20 | -0.14 | -0.10 | -0.01 | 0.00 | - | - | - | - | - | - | - | - | - |
Free Cashflow | -319.7% | -2,178,268 | 991,448 | 1,183,406 | 5,163,168 | -1,525,469 | 3,791,559 | 2,543,892 | 2,193,281 | -177,484 | 1,950,633 | -161,961 | 2,684,148 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -0.3% | 82.00 | 82.00 | 88.00 | 89.00 | 89.00 | 93.00 | 91.00 | 93.00 | 97.00 | 84.00 | 88.00 | 89.00 | 93.00 | 96.00 | 96.00 | 98.00 | 97.00 | 105 | 104 | 108 | 115 |
Current Assets | 1.4% | 36.00 | 36.00 | 42.00 | 44.00 | 44.00 | 46.00 | 49.00 | 44.00 | 45.00 | 46.00 | 47.00 | 47.00 | 49.00 | 50.00 | 49.00 | 46.00 | 45.00 | 50.00 | 49.00 | 52.00 | 58.00 |
Cash Equivalents | 1.2% | 19.00 | 18.00 | 19.00 | 18.00 | 16.00 | 20.00 | 20.00 | 18.00 | 17.00 | 27.00 | 26.00 | 26.00 | 25.00 | 25.00 | 27.00 | 27.00 | 27.00 | 28.00 | 27.00 | 21.00 | 25.00 |
Inventory | -6.1% | 4.00 | 5.00 | 9.00 | 11.00 | 10.00 | 10.00 | 11.00 | 9.00 | 10.00 | 8.00 | 10.00 | 10.00 | 10.00 | 11.00 | 10.00 | 8.00 | 8.00 | 9.00 | 10.00 | 11.00 | 11.00 |
Net PPE | 0.4% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Goodwill | 0% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Liabilities | 3.4% | 54.00 | 53.00 | 52.00 | 53.00 | 53.00 | 57.00 | 52.00 | 53.00 | 56.00 | 42.00 | 41.00 | 41.00 | 46.00 | 50.00 | 48.00 | 49.00 | 48.00 | 53.00 | 52.00 | 54.00 | 59.00 |
Current Liabilities | -5.6% | 26.00 | 28.00 | 27.00 | 27.00 | 26.00 | 29.00 | 25.00 | 24.00 | 25.00 | 19.00 | 18.00 | 19.00 | 23.00 | 26.00 | 24.00 | 23.00 | 19.00 | 24.00 | 21.00 | 22.00 | 28.00 |
Shareholder's Equity | -8.2% | 27.00 | 30.00 | 36.00 | 37.00 | 36.00 | 36.00 | 39.00 | 39.00 | 41.00 | 43.00 | 47.00 | 48.00 | 47.00 | 47.00 | 48.00 | 48.00 | 50.00 | 51.00 | 52.00 | 54.00 | 55.00 |
Retained Earnings | -11.1% | -19.43 | -17.49 | -11.19 | -10.14 | -11.02 | -11.21 | -8.77 | -8.36 | -7.02 | -5.64 | -1.79 | -0.74 | -1.96 | -2.13 | -1.25 | -0.77 | 0.00 | 1.00 | 2.00 | 4.00 | 5.00 |
Shares Outstanding | 0.3% | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 15.00 | 15.00 | 15.00 | 15.00 | 15.00 | 15.00 | - | - | - | - | - | - | - | - | - |
Minority Interest | 12.7% | -0.30 | -0.34 | -0.34 | -0.32 | -0.31 | -0.29 | -0.27 | -0.26 | -0.23 | -0.21 | -0.18 | -0.14 | -0.14 | -0.12 | -0.09 | -0.07 | -0.05 | -0.04 | -0.03 | -0.37 | -0.24 |
Float | - | - | - | - | 12.00 | - | - | - | 17.00 | - | - | - | 24.00 | - | - | - | 31.00 | - | - | - | 57.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -305.4% | -2,136 | 1,040 | 1,237 | 5,235 | -1,418 | 3,638 | 2,635 | 2,331 | -150 | 1,960 | -102 | 2,699 | 1,786 | 854 | 857 | 2,816 | 889 | 857 | 734 | 1,851 | -385 |
Share Based Compensation | -16.1% | 79.00 | 94.00 | 83.00 | 98.00 | 90.00 | 127 | 188 | -27.75 | 160 | 225 | 162 | 192 | 163 | 241 | 262 | 278 | 265 | 378 | 347 | 397 | 364 |
Cashflow From Investing | -122.3% | -58.19 | 261 | -95.07 | -96.81 | -174 | -640 | 681 | -172 | -13,541 | -26.79 | -108 | -48.51 | -318 | -316 | -668 | -201 | -571 | 1,903 | 6,942 | -4,823 | -1,723 |
Cashflow From Financing | 262.8% | 2,422 | -1,487 | -882 | -3,275 | -1,779 | -2,780 | -1,991 | -1,208 | 3,918 | -735 | 383 | -1,903 | -1,298 | -2,430 | -915 | -2,266 | -1,503 | -1,525 | -1,649 | -685 | -1,220 |
Buy Backs | 33.8% | 247 | 184 | 201 | 172 | 188 | 201 | 79.00 | 197 | 566 | 361 | 238 | 485 | 303 | 304 | 333 | 770 | 442 | 899 | 1,362 | 532 | 704 |
Condensed Consolidated Statements of Operations - USD ($) | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
Net revenues | $ 8,497,701 | $ 9,224,638 |
Costs and expenses: | ||
Cost of products sold | 1,575,542 | 1,250,264 |
Selling and marketing | 4,154,588 | 4,277,318 |
Research and development | 1,158,253 | 1,499,670 |
General and administrative | 2,367,907 | 2,498,993 |
Amortization | 1,110,661 | 1,230,071 |
Total costs and expenses | 10,366,951 | 10,756,316 |
Operating loss | (1,869,250) | (1,531,678) |
Interest income | 96,746 | 50,190 |
Other income | 0 | 1,847,065 |
Interest expense | (118,526) | (186,353) |
Income (loss) before income taxes | (1,891,030) | 179,224 |
Income tax expense | (11,442) | (6,938) |
Net income (loss) | (1,902,472) | 172,286 |
Net (income) loss at subsidiary attributable to noncontrolling interests | (43,791) | 19,898 |
Net income (loss) attributable to common shareholders | $ (1,946,263) | $ 192,184 |
Earnings (loss) per share attributable to common shareholders | ||
Basic (in USD per share) | $ (0.14) | $ 0.01 |
Diluted (in USD per share) | $ (0.14) | $ 0.01 |
Weighted-average shares outstanding | ||
Basic (in shares) | 14,098,022 | 14,359,322 |
Diluted (in shares) | 14,098,022 | 14,587,843 |
Condensed Consolidated Balance Sheets - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 18,548,485 | $ 18,321,624 |
Accounts receivable, net | 10,647,267 | 9,758,176 |
Inventories, net | 4,327,526 | 4,609,362 |
Prepaid and other current assets | 2,682,673 | 3,025,248 |
Total current assets | 36,205,951 | 35,714,410 |
Non-current inventories | 12,915,896 | 12,804,529 |
Property and equipment, net | 369,499 | 367,903 |
Intangible assets, net | 21,522,441 | 22,607,918 |
Goodwill | 914,000 | 914,000 |
Operating lease right-of-use assets | 6,521,088 | 6,674,394 |
Other assets | 3,060,643 | 2,692,921 |
Total assets | 81,509,518 | 81,776,075 |
Current liabilities: | ||
Accounts payable | 13,075,764 | 14,037,629 |
Operating lease current liabilities | 362,244 | 348,092 |
Other current liabilities | 12,987,372 | 13,596,528 |
Total current liabilities | 26,425,380 | 27,982,249 |
Revolving line of credit | 16,084,144 | 12,784,144 |
Operating lease non-current liabilities | 5,200,148 | 5,296,247 |
Other long-term liabilities | 6,610,294 | 6,453,566 |
Total liabilities | 54,319,966 | 52,516,206 |
Shareholders’ equity: | ||
Common stock—no par value; 100,000,000 shares authorized; 14,159,954 and 14,121,833 shares issued and outstanding as of March 31, 2024 and December 31, 2023 , respectively | 46,923,757 | 47,091,602 |
Accumulated deficit | (19,434,424) | (17,488,161) |
Total shareholders’ equity | 27,489,333 | 29,603,441 |
Noncontrolling interests | (299,781) | (343,572) |
Total equity | 27,189,552 | 29,259,869 |
Total liabilities and equity | $ 81,509,518 | $ 81,776,075 |
Mr. A. J. Kazimi MBA | |
cumberlandpharma.com | |
Pharmaceuticals | |
85 |